Jason Napodano

It turns out you can have too much of a good thing. The 1,000-plus immunotherapy trials and competition to develop proprietary versions of virtually the same drugs may prove inhibitory to cancer research, according to the New York Times. The conditions leave clinical researchers competing for the...

Neither Republicans nor Democrats are eager to cut the National Institutes of Health funding by the president’s suggested $5.8 billion, but with the proposal still on the table, the sum is not yet safe. And as 18 percent of the current $31.7 billion budget hangs in the balance, more Americans...

The beginning of the year has started with four consecutive sell-offs in the S&P 500. Sectors have been hit by a bevy topics ranging from interest rates, Chinese markets, and terrorism. There has been a different type of trend among biotech stocks. Over the past week of trading, many...

The "specialty pharma" space has received a lot of attention this week, and it's not very positive. It began on Monday with a New York Times article focusing on "Prescriptions Made easy." The market felt the effects on Wednesday when Citron Research came out with a...